A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE009 (AUS) · Dr. Novak
consented 2023-09-08
Adverse events
Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2024-01-22 (study day 130); relationship: N
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2024-06-19 (study day 279); relationship: not assessed
Grade 4 Fatigue — outcome: RECOVERED/RESOLVED; onset 2024-07-09 (study day 299); relationship: not assessed; serious criteria: life-threatening
Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2024-11-08 (study day 421); relationship: Y
Grade 2 Decreased appetite — outcome: UNKNOWN; onset 2024-12-14 (study day 457); relationship: not assessed
Data queries
No data queries.